In an unprecedented exploration into the dynamic interplay between microbiota and host physiology, a groundbreaking study has illuminated the pivotal role of microbial enzymes in modulating gut motility through reactivation of host androgens. Published in Nature Neuroscience in 2026, this research uncovers how microbial metabolism intricately directs enteric neuronal circuits, reshaping our understanding of the gut-brain axis with profound implications for human health and disease.

The study embarks from the well-documented influence of androgens—steroid hormones traditionally associated with male traits—on various physiological systems. While systemic androgen effects have been explored, this investigation probes deeper into localized reactivation mechanisms within the gut environment, where microbial communities reside densely. Researchers reveal that resident gut microbes possess enzymatic functions capable of converting androgen precursors back into their active forms, effectively reawakening hormonal signaling within the enteric nervous system.

Employing a sophisticated combination of metabolomic profiling, genetic manipulation, and electrophysiological techniques, the team identified key bacterial taxa responsible for this enzymatic reactivation. Notably, these microbial metabolic activities were found to significantly enhance the bioavailability of active androgens in the gut lumen, directly influencing neuronal excitability and, consequently, gut motility patterns. This discovery bridges a vital gap between microbiome functionality and neuroendocrine regulation that had remained elusive until now.

Central to the findings is the concept that androgen reactivation by microbial enzymes fine-tunes enteric neuronal output, orchestrating peristaltic reflexes and smooth muscle contractions essential for intestinal transit. Through targeted in vivo experiments, the researchers demonstrated that disruption of this microbial androgen metabolism altered gut motility, resulting in either hypo- or hypermotility phenotypes. These effects were reversible upon restoration of the microbial enzymatic activity, suggesting a highly dynamic and plastic system governed by host-microbiome feedback loops.

Beyond the immediate mechanistic insights, this study challenges conventional paradigms by positioning gut microbes as active endocrine modulators rather than passive inhabitants. The realization that microbial metabolism can recalibrate host hormonal circuits highlights novel avenues for therapeutic intervention in gastrointestinal disorders characterized by dysmotility, such as irritable bowel syndrome and chronic constipation. Modulating microbial androgen reactivation could become a precision medicine strategy tailored to restore normal gut function.

Intriguingly, the researchers also unveiled sexually dimorphic responses in the interplay between microbial androgen reactivation and enteric neuron function. Male and female mice exhibited distinct motility patterns contingent upon variations in microbial enzymatic profiles and host androgen sensitivity, underscoring the importance of considering sex as a biological variable in gut-neuroendocrine research. This facet deepens our appreciation of individualized host-microbe interactions shaping health outcomes.

At the molecular level, the study elaborates on how microbial enzymes such as hydroxysteroid dehydrogenases catalyze reversible conversions between inactive androgen conjugates and their active counterparts. These enzymatic reactions take place in close proximity to enteric neurons, facilitating paracrine signaling that modulates neuronal firing rates and neurotransmitter release. This finely tuned mechanism enables the microbiome to exert sophisticated control over gut motility beyond mere metabolite production.

Furthermore, the research integrates advanced imaging modalities to visualize neuronal activity in real-time, correlating enhanced androgen availability with increased calcium fluxes and action potential frequency within enteric ganglia. This real-time functional evidence solidifies the link between microbial metabolic activity and neurophysiological outputs, offering a multi-dimensional perspective of gut regulatory networks. The convergence of metabolic and neuronal data lends robust credibility to the proposed model.

From an evolutionary standpoint, the elucidation of microbial androgen reactivation mechanisms hints at a co-evolved symbiotic relationship where microbes contribute to optimizing host intestinal function. This evolutionary insight expands the framework of mutualism, suggesting that microbiota-derived modulation of hormone signaling constitutes an adaptive advantage for maintaining digestive efficiency. Such findings provide fertile ground for evolutionary biology and microbiome research intersections.

The translational potential of these discoveries is immense. By identifying specific microbial enzyme targets, pharmaceutical development can aim to design modulators or probiotics that enhance or inhibit androgen reactivation within the gut, thereby controlling motility disorders. Moreover, these microbial pathways might influence systemic endocrine functions given the interconnectivity between enteric neurons and central nervous system circuits, opening exciting possibilities for neurogastroenterology.

Intricately, the study also discusses the feedback mechanisms wherein host androgens modulate microbial community composition and metabolic activity, establishing a bidirectional communication loop. This dynamic feedback ensures homeostasis by synchronizing microbial function with host hormonal status, representing an elegant biological system integrating metabolic, neuronal, and microbial domains. Such complexity underscores the need for holistic approaches in future gut-brain axis investigations.

Given the widespread prevalence of gut motility disorders, the identification of microbial androgen reactivation as a key regulatory mechanism invites renewed scrutiny of microbiome-targeted therapies. Dietary interventions, antibiotics, and microbiota transplants could inadvertently perturb these enzymatic activities, altering gut function. Therefore, medical practices may need to incorporate microbiome endocrine considerations to optimize patient outcomes and minimize adverse effects.

In conclusion, this seminal study redefines the microbial contribution to host physiology by unveiling a novel enzymatic process through which gut bacteria reactivate androgens, orchestrating enteric neuronal regulation of motility. This intricate biochemical crosstalk exemplifies the emerging frontier of microbiome-endocrine interactions with vast implications for biology, medicine, and therapeutics. As we unravel these complex dialogues, the prospect of leveraging microbial endocrinology to modulate health becomes an exciting reality.

The transformative insights gained here invite a paradigm shift: the gut microbiome is not merely a metabolic organ but an endocrine entity capable of recalibrating host neurophysiological processes. This revelation paves the way for integrative research endeavors bridging microbiology, endocrinology, neuroscience, and clinical medicine, ultimately advancing personalized healthcare in gastrointestinal and systemic diseases. Such interdisciplinary synergy heralds a new epoch of microbiome-informed biomedical breakthroughs.

As the field advances, further studies will doubtless explore how microbial androgen reactivation interfaces with other hormonal axes and systemic immunity, deepening our comprehension of host-microbiome symbiosis. The interplay between microbial enzymatic activities and host signaling cascades likely extends beyond gut motility, influencing metabolism, mood, and behavior. The future of human health hinges upon decoding these microbial endocrine networks and harnessing their potential.

---

Subject of Research: Microbial enzymatic reactivation of host androgens and their role in enteric neuronal regulation of gut motility.

Article Title: Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility.

Article References:
Lagomarsino, V.N., Robinson, A., Mitchell, P.E. et al. Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02321-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-026-02321-0

In the intricate dance of life’s blueprint, DNA has long been celebrated as the master code guiding organismal development and heredity. Yet, the regulation of gene activity—how genes switch on and off with exquisite precision across different cellular contexts and environmental cues—extends beyond the mere sequence of nucleotides. This regulation hinges on a complex layer of control known as epigenetics. Epigenetics encompasses chemical modifications of DNA and histone proteins that influence gene expression without altering the underlying genetic code. Among these modifications, DNA methylation, the addition of methyl groups to cytosine bases within the genome, has emerged as a pivotal mechanism modulating gene activity.

In vertebrates such as mammals, a robust epigenetic “resetting” occurs shortly after fertilization. This sweeping reprogramming strips away most inherited methylation marks, effectively erasing epigenetic memories acquired during the parents’ lifetimes and thus safeguarding embryonic development from potentially deleterious epimutations. However, this epigenetic reprogramming does not appear universal across the animal kingdom. In numerous invertebrates, including marine organisms like corals, worms, sea anemones, and sea urchins, this global erasure seems conspicuously absent, hinting at fundamental evolutionary divergences in epigenetic regulation.

A groundbreaking study recently explored these differences by experimentally disrupting DNA methylation in the starlet sea anemone, Nematostella vectensis, a cnidarian species that occupies a key phylogenetic position near the base of animal evolution. By selectively removing methylation marks within its genome, researchers sought to unravel methylation’s functional importance in an organism where typical epigenetic resetting is missing. Contrary to expectations, the anemones developed normally, even in the near complete absence of DNA methylation. This surprising resilience suggested that DNA methylation’s primary role might not be to orchestrate gene expression as traditionally envisioned.

Rather than broadly compromising gene regulation, the loss of methylation predominantly unleashed the activity of transposable elements—often referred to as “jumping genes” or selfish DNA sequences—that reside within actively transcribed genes. These genetic elements possess the capacity to move within the genome, potentially inserting themselves into critical coding or regulatory regions. If not tightly suppressed, such mobilization can disrupt gene function, precipitate genomic instability, and impair normal development. The discovery that methylation chiefly acts to restrain these disruptive elements underscores an ancestral genomic defense mechanism preserved across evolutionary epochs.

Dr. Alex de Mendoza, a leading expert in evolutionary epigenomics at Queen Mary University of London, highlighted the profound implications of these findings. Because invertebrate species like sea anemones lack the typical epigenetic cleansing during early development, abnormal methylation patterns can persist and transmit to subsequent generations. This epigenetic inheritance modulates gene expression profiles beyond what genetic code alone dictates, revealing an additional layer of heritable biological information. Such phenomena demonstrate how experimentally introduced epigenetic variation can traverse generational boundaries in animals, challenging the long-held tenet that only DNA sequence changes are heritable.

Delving deeper, the research offers a novel perspective on the evolutionary trajectory of DNA methylation. Initially, this modification appears to have evolved primarily as a genomic safeguard, protecting coding sequences from the disruptive capacity of transposable elements. Over time, in mammalian lineages, this molecular machinery was co-opted and expanded to execute broader developmental regulatory roles—acting to silence one X chromosome in females and regulate complex tissue-specific gene expression programs. The study thus illuminates how molecular systems adapt and diversify, transforming ancient genomic guardians into sophisticated regulators of vertebrate biology.

Moreover, the lack of full epigenetic reprogramming in cnidarians suggests these organisms possess an inherent capacity to maintain inherited epigenetic states, providing a reservoir of variation for natural selection to act upon. Such stable transmission of epigenetic marks without underlying genetic mutation may represent an unappreciated source of phenotypic diversity and evolutionary innovation. This challenges the paradigm that heritable biological change requires DNA sequence alteration, expanding evolutionary biology’s conceptual framework to include epigenetic mechanisms in shaping organismal adaptation.

This work also emphasizes the intricate interplay between epigenetics and genome integrity. Transposable elements constitute a significant fraction of animal genomes, and their regulation is paramount to preventing genomic chaos. DNA methylation emerges as a critical regulator, keeping these elements silenced, especially within gene bodies, where their disruptive potential is highest. The failure of this epigenetic control unleashes internal genomic parasites that can jeopardize normal gene function and organismal survival.

Intriguingly, the seemingly paradoxical normal development of methylation-deficient anemones underscores redundancy and plasticity in gene regulatory networks. The absence of overt developmental defects suggests that alternative mechanisms can compensate for lost methylation-mediated repression. This resilience hints at a genome architecture finely tuned through evolution to maintain stability even when key regulatory systems falter, underscoring the robustness of biological systems.

The study not only deepens our understanding of DNA methylation’s ancestral functions but also opens avenues for exploring how epigenetic inheritance influences ecological and evolutionary dynamics in marine ecosystems. Cnidarians represent ecologically vital keystone species; thus, their capacity to pass on epigenetic traits may impact resilience and adaptation in changing oceans, with implications for biodiversity and conservation.

Beyond evolutionary insights, the research sets a foundation for new epigenetic models that integrate heritable methylation patterns with genome defense and gene regulation. It challenges researchers to reconsider the boundaries between genetic and epigenetic inheritance and to explore how ancient molecular mechanisms continue to shape life’s diversity from sea anemones to humans. This deeper comprehension may ultimately inform biomedical approaches targeting epigenetic modifications in disease and developmental biology.

In sum, this landmark investigation redefines DNA methylation’s evolutionary purpose, positing that its primordial function was genome protection rather than gene regulation per se. The delicate dance between epigenetic marks, transposable elements, and genetic regulation emerges as a foundational axis steering animal evolution and developmental fidelity. As we dive deeper into epigenomes across diverse species, the revelations from humble sea anemones remind us that evolution often innovates by repurposing age-old molecular tools in unexpected, transformative ways.

---

Subject of Research: Not applicable

Article Title: Gene body methylation suppresses intragenic transcription and permits epigenetic inheritance in a cnidarian

Web References: 10.1038/s41559-026-03090-6

Image Credits: Karmannye Chaudhary

Keywords: Evolutionary biology, epigenetics, DNA methylation, transposable elements, epigenetic inheritance, cnidarian, genome stability, gene regulation, Nematostella vectensis

In the rapidly evolving arena of synthetic biology, precise gene regulation remains both a crucial goal and formidable challenge. Bacteria, with their intricate genetic networks and vital roles in biotechnology, serve as prime targets for engineering sophisticated gene control systems. Now, a groundbreaking study published in Nature Biotechnology unveils an innovative strategy harnessing an attenuated form of Cas13d—a powerful RNA-targeting CRISPR effector—to achieve programmable, multiplexed, and orthogonal gene regulation in Escherichia coli. This advancement opens unprecedented avenues for dynamic bacterial gene control, enabling nuanced modulation of gene expression with high specificity and minimal cytotoxicity.

Traditional CRISPR systems like Cas9 have revolutionized DNA editing, yet RNA-targeting effectors such as Cas13 bring unique advantages for reversible and tunable regulation without permanent genomic alterations. However, the application of Cas13 in bacteria has encountered a significant barrier: collateral cleavage activity. Wild-type Cas13 exhibits nonspecific RNA degradation once activated, leading to cytotoxicity and growth inhibition, thus impeding its widespread use for precise transcriptional tuning in prokaryotic cells. Overcoming this limitation required a reimagination of the Cas13 protein architecture.

The researchers addressed this by adopting a rational protein engineering approach, focusing on attenuating Cas13d’s RNase activity while preserving its targeted RNA knockdown capacity. They identified and excised flexible regions within the Cas13d protein structure hypothesized to contribute to unwanted collateral cleavage. This targeted truncation yielded a spectrum of Cas13d variants with tunable enzymatic activity. Notably, these engineered Cas13d proteins maintained their ability to silence specific transcripts efficiently, yet exhibited drastically reduced cytotoxicity, as evidenced by a remarkable 2.2-fold increase in bacterial growth optical density compared to cells harboring wild-type Cas13d.

Beyond simply dampening RNase activity, this attenuated Cas13d toolkit demonstrated an exquisite level of functional versatility, modulated by subtle changes in CRISPR RNA spacer design. By introducing proximal mismatches at the 5′ end of the spacer sequences, the system enables a programmable switch among three distinct modes of gene regulation: translation inhibition, targeted degradation of polycistronic mRNAs, and CRISPR activation at the translation level via fusion to the bacterial initiation factor IF3. This modularity allows tailored control strategies for diverse applications, ranging from silencing deleterious genes to upregulating beneficial pathways.

A particularly compelling aspect of this work is the system’s capability to exert multiplexed and orthogonal regulation within polycistronic transcripts—bacterial mRNAs that encode multiple proteins in a single RNA molecule. By designing guide RNAs targeting specific genes within these operons, the researchers successfully demonstrated simultaneous and independent control of individual gene expression. This level of granularity in bacterial gene editing was previously unattainable with conventional CRISPR tools and holds immense potential for engineering complex synthetic circuits with multiple inputs and outputs.

To showcase the practical utility of this attenuated Cas13d system, the team applied it to a classic microbial biotechnology challenge: optimization of lycopene biosynthesis in E. coli. Lycopene, a valuable carotenoid with health and industrial relevance, is synthesized via a multi-enzyme metabolic pathway that requires careful balancing of enzyme levels and fluxes. Employing their refined Cas13d-based regulatory toolkit, the researchers fine-tuned essential and competing genes within this pathway dynamically. The resulting pathway rewiring not only enhanced lycopene yields significantly but also maintained cell vitality, illustrating the harmony between metabolic optimization and cell health achievable with this sophisticated regulatory platform.

The implications of this advance ripple well beyond E. coli or lycopene synthesis. The modular, tunable nature of attenuated Cas13d effectors paves the way for next-generation microbial synthetic biology applications—from bioproduction of complex molecules to living biosensors that respond rapidly to environmental cues. The reversible and multiplexed control mechanism offers a potent toolset for probing fundamental bacterial gene function and constructing synthetic circuits with unprecedented precision.

Moreover, this technology elegantly sidesteps the permanent genomic disruptions characteristic of DNA-targeting CRISPR tools. By targeting RNA transcripts post-transcriptionally, this approach enables reversible modulation of gene expression states, allowing researchers to study temporal dynamics in bacterial physiology or develop programmable microbes that can switch functionalities in response to stimuli.

The engineering of Cas13d itself involved exploiting detailed structural and functional knowledge. Flexible regions previously overlooked were pinpointed as critical determinants for collateral cleavage. This insight underscores the power of combining structural biology with synthetic biology to reimagine natural effectors as finely controllable tools rather than blunt instruments. It opens the door for similar attenuation strategies to be applied to other RNA-targeting nucleases, amplifying the toolkit available for RNA biology and biotechnology.

The use of proximal spacer mismatches to toggle between inhibition, degradation, and activation states represents a clever exploitation of CRISPR RNA–target complementarity rules. This innovation decouples RNase activity from binding affinity and allows a single engineered Cas13d protein to perform multiple regulatory roles without further protein engineering, streamlining system design and increasing flexibility.

Importantly, the orthogonal targeting within polycistronic mRNAs highlights the potential for sophisticated bacteria-wide gene regulation at the RNA level. Since many bacterial operons encode functionally linked proteins, this ability to recalibrate individual gene outputs independently provides a powerful lever to dissect and rewire bacterial gene networks with minimal disturbance to overall cellular integrity.

The improved growth performance of bacteria expressing attenuated Cas13d variants is a vital advancement for biotechnological deployment. The reduced toxicity facilitates higher cell densities and longer cultivation times, improving production scalability. This contrasts sharply with previous Cas13 systems, where collateral damage to cellular RNAs often stagnated growth and limited practical utility.

From therapeutic applications aiming to modulate microbial communities to industrial biosynthesis frameworks requiring dynamic metabolic flux control, the attenuated Cas13d toolkit stands as a versatile and impactful innovation. It bridges longstanding gaps in RNA-targeting technologies, balancing potency with biocompatibility and programmability.

In conclusion, this study represents a seminal step in realizing dynamic, multiplexed, and reversible gene control in bacteria through rational engineering of Cas13d. By attenuating collateral cleavage and introducing spacer design-based functional switching, the authors have delivered a powerful RNA regulatory toolkit poised to transform microbial synthetic biology and biotechnology. Future research will undoubtedly explore expanding this system to diverse bacterial species, integrating it with other synthetic genetic elements, and harnessing its potential for real-time cellular reprogramming.

The scientific community is certain to embrace this versatile platform, which not only enhances our capacity to engineer bacteria but also deepens our understanding of RNA biology and CRISPR functionality. As synthetic biology marches forward, such innovations redefine the frontier of microbial gene control, unlocking new possibilities from medicine to sustainable biomanufacturing.

---

Subject of Research:
Programmable, multiplexed, orthogonal gene control in bacteria using engineered, attenuated Cas13d systems.

Article Title:
Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems.

Article References:
Tong, S., Qin, Y., Sun, Y. et al. Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03160-x

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41587-026-03160-x

President Donald Trump signed an executive order Tuesday creating a "voluntary framework" for AI companies to share their frontier models with the federal government before they're released "to promote secure innovation and strengthen the cybersecurity of critical infrastructure."

The order says the US AI industry has succeeded in part "because we refuse to stifle this innovation with overly burdensome regulation," but that it also recognizes new AI capabilities come with security risks. Accordingly, it directs several federal agencies to come up with a framework to "assess the advanced cyber capabilities of AI models" before they're releas …

Read the full story at The Verge.

AI player Anthropic confidentially submitted paperwork for its proposed initial public listing ahead of rival OpenAI, while also giving the European Union’s cybersecurity body preliminary access to its Mythos AI tool.

The draft registration statement submitted to the US Securities and Exchange Commission gives the company the option to go public after the agency completes its review.

Anthropic stated the number of shares to be offered and the price have not yet been set.

News of the IPO move came the same day (1 June) Bloomberg reported Anthropic will give ENISA, the European Union’s cybersecurity agency, access to Mythos through Project Glasswing, an initiative which allows organisations to test Mythos’ capabilities before a wider release.

There are growing concerns among governments over the security implications of Mythos, which Anthropic released to some private companies in April.

Anthropic communicated the decision to the European Commission over the weekend.

EC spokesperson Thomas Regnier confirmed the development to Mobile World Live (MWL) followed several weeks of productive discussions.

 “We welcome the latest developments on potential future access,” he said. “This is the result of the Commission’s strong bilateral cooperation and engagement with Anthropic, a leading frontier AI company.”

The EC was careful to frame the moment not as a resolution but as a starting point to work with the US administration, Anthropic and additional AI companies such as OpenAI.

“This is a shared challenge, and we are intensifying our discussions with like-minded partners, including the United States,” Regnier said.

The plan is for ENISA to join Project Glasswing, the coalition Anthropic announced in April which includes Amazon, Apple, AT&T, T-Mobile US, Microsoft, Google, CrowdStrike, Nvidia and Palo Alto Networks, among others.

The post Anthropic confidentially files for IPO appeared first on Mobile World Live.

Meta Platforms reportedly acknowledged its controversial employee surveillance programme captures data from employees outside the US, raising fresh legal questions in Europe.

Reuters reported internal documentation it reviewed showed the company’s Model Capability Initiative (MCI) does capture data outside of the US.

MCI was introduced last month as a tool to record how US-based employees interact with their work computers by tracking mouse movements, clicks and navigation patterns across more than 200 apps and websites.

The goal of MCI is to use the employee-generated data to train AI agents capable of performing coding and white-collar tasks.

Meta told staff the programme is confined to US devices and stated safeguards are in place to protect sensitive information.

The news agency noted Meta acknowledged in a question-and-answer document provided to employees MCI will capture the contents of any emails or direct messages sent to US personnel, regardless of the sender’s ⁠location.

Meta spokesperson Dave Arnold told Reuters the company notified non-US employees the tool was running on the machines of US-based colleagues they might correspond with, describing the step as one of transparency.

A representative for Meta told Mobile World Live: “We’ve been clear that this tool is for US-based personnel only, and in the interest of transparency, we notified non-US employees that it was deployed on the computers of US colleagues they may email or chat with in the normal course of business.”

“We carefully considered and mitigated potential privacy risks in both the development and deployment of this tool, and we are committed to complying with applicable laws and regulations.” 

New regulatory exposure
Reuters stated the disclosure introduces new regulatory exposure in Europe, where technology companies are already fighting a series of heated legal battles over data collection.

Under the EU’s GDPR rules, the news site explained companies must establish a clear legal basis for processing personal data, disclose what is being collected and satisfy strict conditions around sensitive categories of information.

Kleanthi Sardeli, a legal expert at privacy advocacy group NOYB, told the news site even limited or incidental capture of EU employee data could put Meta in breach of GDPR rules.

A key question, she said, is whether data originally gathered for work communications can lawfully be repurposed to train an AI model.

The post Meta tracking tool raises EU GDPR concerns appeared first on Mobile World Live.

The European Union (EU) is pressing for deeper talks with the US administration over advanced AI models, and at the heart of the conversation is Anthropic’s Mythos.

There are growing concerns among governments over the security implications of Mythos, which Anthropic released to private companies in April.

Its release triggered an immediate wave of concern when it surfaced the model could identify tens of thousands of software vulnerabilities at a scale no previous system had demonstrated.

The AI player introduced its Mythos model on 7 April, under the auspices of Project Glasswing, to a limited number of technology companies including Amazon Web Services, Apple, Nvidia and Google.

Anthropic expects to bring Mythos-class models to all customers in the coming weeks.

Bloomberg previously reported the EU made limited progress in securing access to details of vulnerabilities Anthropic’s Mythos AI model could reveal.

European Commission spokesperson Thomas Regnier told Mobile World Live (MWL) the agency has had several meetings with Anthropic to understand the capability of the model, its implications for the cybersecurity of the EU and Anthropic’s plan around Project Glasswing.

“We will keep discussing with the company the cyber capabilities and risks of its latest model,” he stated.

CNBC reported Anthropic has yet to grant the EU, its AI office or any government organisations outside of the US, aside from the UK’s AI Security Institute, preview access to Mythos.

Since August 2025, the European Commission’s AI Office has held regular technical meetings with Anthropic tied to the General-Purpose AI Code of Practice, to which the company is a signatory.

A spokesperson for the EC noted Mythos is not a one-off as a “new wave of powerful models are coming to the market”.

The EC stated parallel progress is being made towards releasing OpenAI’s GPT-5.5-Cyber to trusted EU entities.

The EC spokesperson told MWL it is intensifying discussions with the US, “particularly on the most advanced AI models, including those with cyber capabilities”.

“Cybersecurity is a shared priority and we have agreed to mutually recognise our respective standards in this area,” the spokesperson stated.  “On EU side, we are also stepping up our cyber defences through targeted investments in AI and supercomputing.”

The post EU pushes for access to Anthropic model as fears grow appeared first on Mobile World Live.

In a groundbreaking study published in Nature Communications, researchers have unveiled a striking compensatory mechanism that could revolutionize the understanding and treatment of mitochondrial disorders, particularly Leigh-like encephalopathy linked to mutations in the COXFA4 gene. This research elucidates the role of a previously underappreciated mitochondrial protein, COXFA4L2, whose upregulation appears to preserve cytochrome c oxidase activity despite genetic impairments, offering new hope for patients grappling with this debilitating neurodegenerative condition.

Leigh-like encephalopathy is a devastating disorder characterized by progressive neurodegeneration arising from defects in mitochondrial respiratory chain complexes. The cytochrome c oxidase complex, also known as complex IV, plays a crucial role in cellular respiration by facilitating electron transfer to oxygen, thereby driving ATP production. Mutations in the COXFA4 gene, integral to complex IV assembly or stability, severely disrupt this process, leading to energy deficits in neurons. Until now, treatment options have been limited, largely supportive, and ineffective in halting disease progression.

The newly published research by Falabella, Lopez Calcerrada, Aref, and colleagues dives deep into mitochondrial homeostasis, focusing on how the cell compensates for COXFA4 dysfunction. They discovered that COXFA4L2, a paralogous protein sharing structural similarity with COXFA4, experiences notable upregulation in cells harboring COXFA4 mutations. This expression enhancement was not only observed in cellular models but also validated in patient-derived samples, underscoring its biological relevance.

Functionally, COXFA4L2 appears to integrate into the cytochrome c oxidase complex, partially substituting for the defective COXFA4 subunit. Biochemical analyses revealed that mitochondria expressing higher levels of COXFA4L2 maintain a residual level of complex IV activity, preserving oxidative phosphorylation capacity to a greater extent than previously believed possible under such genetic constraints. This residual activity correlates with improved cellular viability and suggests a natural resilience mechanism the cell employs in face of mitochondrial distress.

From a molecular standpoint, the study utilized cryo-electron microscopy (cryo-EM) to resolve the structural incorporation of COXFA4L2 within the complex IV superstructure. The data illuminated subtle conformational adaptations in the complex permitting COXFA4L2 substitution without significantly compromising enzymatic function. This structural insight highlights an elegant evolutionary adaptation allowing mitochondrial function to persist when canonical components are impaired.

The implications of this investigation extend beyond Leigh-like encephalopathy. By unraveling how COXFA4L2 mediates functional rescue, these findings open avenues for targeted therapies that could enhance or mimic this compensatory effect. Gene therapy approaches aiming to upregulate COXFA4L2 or small molecules designed to stabilize its incorporation within complex IV could represent transformational strategies in managing mitochondrial respiratory deficiencies.

Moreover, the research team explored regulatory pathways controlling COXFA4L2 expression, identifying transcription factors responsive to mitochondrial stress signals that drive its induction. This mechanistic understanding presents additional pharmacological targets to amplify the body’s intrinsic protective response to mitochondrial dysfunction. Future studies are poised to examine these regulatory cascades across diverse mitochondrial pathologies to assess generalizability.

Clinically, the discovery of COXFA4L2’s role raises the potential for biomarkers reflective of this compensatory response, aiding in early diagnosis and prognostic evaluation of Leigh-like encephalopathy. Quantifying COXFA4L2 levels or activity in patient biofluids could provide a minimally invasive means to monitor disease status or therapeutic efficacy in real time, enhancing personalized medicine efforts.

The epidemiological context also warrants attention. Mitochondrial disorders collectively affect millions worldwide yet remain underdiagnosed due to their complex phenotypic presentations. Insights from this study encourage renewed screening initiatives in genetically at-risk populations, particularly focusing on COXFA4 mutations where COXFA4L2 upregulation might serve as both a diagnostic and therapeutic marker.

Beyond translational and clinical perspectives, this compelling work enriches foundational mitochondrial biology. It exemplifies how gene paralogs can evolve to furnish adaptive flexibility in critical bioenergetic processes, ensuring cellular survival amidst genetic perturbations. Such plasticity is likely a widespread but underexplored phenomenon in mitochondrial function that warrants further exploration.

The interdisciplinary team combined molecular genetics, biochemistry, high-resolution imaging, and clinical neurology expertise to deliver comprehensive insights into this complex biological problem. Their integrative approach exemplifies the power of cross-field collaboration to decode sophisticated cellular phenomena with direct human health implications.

In summation, the revelation that COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy constitutes a paradigm shift. It not only expands the molecular understanding of mitochondrial disease pathogenesis but also heralds tangible pathways toward innovative treatments capable of mitigating neurodegeneration and improving patient quality of life.

As the scientific community digests these striking findings, the path forward is clear: accelerate translational research focusing on COXFA4L2, optimize therapeutic modalities harnessing its protective properties, and amplify efforts to identify patients who stand to benefit. The promise of enhancing mitochondrial resilience through leveraging endogenous compensatory pathways offers a beacon of optimism in an arena historically marked by therapeutic paucity.

The future holds exciting prospects for mitochondrial medicine, inspired and propelled by discoveries such as these. By unveiling nature’s own molecular adaptations, we edge closer to conquering diseases once deemed inexorable, reaffirming the profound potential residing within cellular biology to inform and transform clinical care on a global scale.

---

Subject of Research: Mitochondrial dysfunction and compensatory mechanisms in COXFA4-related Leigh-like encephalopathy

Article Title: COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy

Article References:
Falabella, M., Lopez Calcerrada, S., Aref, J. et al. COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73455-9

Image Credits: AI Generated

European Commission (EC) EVP Henna Virkkunen unveiled a proposal for the allocation of the 2GHz spectrum band for mobile satellite services, with the lion’s share set to be reserved for companies based in the European Union (EU).

Under the plan, the EC would allocate a third of the spectrum for government and critical communications use, with the remainder available for commercial applications including direct-to-device smartphone connectivity and IoT applications.

Virkkunen stated the segment used for critical communications and government agencies would be awarded to an operator within the EU which would be tasked with ensuring integration with IRIS2 infrastructure.

Half of the proportion available for commercial use would be reserved for providers based in the EU and the remainder open to bids from companies based anywhere.  

She noted earmarking allocations to local operators would “encourage the diversification of suppliers and incentivise” entry into the market.

The EC is planning an EU-level selection process for assignment of the spectrum to ensure regulatory consistency across the bloc and allow operators to provide cross-border services.

Licences currently active for the band were allocated on an EU-wide basis.

Critical
Virkkunen said the 2GHz band is foundational to providing “satellite and terrestrial connectivity directly to our mobile devices, ensuring that all areas in the EU, and namely those where terrestrial networks are unavailable, are equipped with voice and internet connectivity”.

Noting “large networks of low Earth orbit satellites are becoming the space version” or mobile towers, she added they also pave the way for 6G.

“In short, this band is absolutely vital for our citizens, businesses and governments alike,” she added, arguing the EC’s proposal would aid in aims to boost Europe’s competitiveness and security, along with embracing “new technological possibilities”.

Although opening the way for big name US operators including Starlink and Amazon Leo to grab allocations, the move to reserve a large proportion for EU-based entities fits with a recent push around technology sovereignty and attempts to bolster local companies.

The post EC proposes local players get bulk of MSS spectrum appeared first on Mobile World Live.